Strategic Focus Late-stage specialty pharma addressing life-threatening CNS edema with unmet medical needs, presenting a high-value niche opportunity for partnerships with large academic centers and critical care networks pursuing stroke and brain injury therapies.

Clinical Momentum Recent press coverage of Phase 2 and Phase 3 CIRARA data at the International Stroke Conference enhances credibility and can be leveraged to initiate partnerships with payer pilots, clinical trial enrollments, and KOL-led advocacy.

Market Reach Addressable market includes diverse CNS edema indications such as large hemispheric infarction and brain injuries; explore collaborations with hospital systems handling stroke units, neurocritical care, and neurosurgery to accelerate adoption.

Funding Leverage Current revenue and $18M funding position the company to invest in early access programs, payer engagement, and regional pilots; align value propositions around mortality/morbidity reductions and potential cost savings.

Competitive Position Distinct focus on intravenous glyburide for edema offers a differentiator from broader CNS therapies; target relationships with large pharma partners or CROs with existing neurocritical care portfolios to scale development and commercialization.